News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CureTech Ltd. Announces Encouraging Phase I Clinical Trial Results In Cancer Patients With Its Monoclonal Antibody CT-011



10/19/2005 5:13:15 PM

YAVNE, Israel--(BUSINESS WIRE)--April 11, 2005-- CT-011 Was Well Tolerated with No Treatment Related Toxicities; Clinical Responses Were Observed in Several Patients Seven to Eight Months Post Treatment CureTech Ltd, a biotechnology company focused on the research, development and commercialization of novel, broad-spectrum, immune-modulating products for the treatment and control of cancer, announced today completion of its Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies. The purpose of this first in human clinical study, which took place at the Chaim Sheba Medical Center in Tel-Hashomer, Israel, was to evaluate the safety and determine the maximal tolerated dose of CT-011 single intravenous administration in cancer patients. The safety profile of CT-011 was evaluated in 17 patients suffering from advanced-stage hematological malignancies. CT-011 was given in a single 5h IV infusion at escalating doses. One patient, at the lowest level, was re-enrolled five months subsequent to the first administration at a higher dose level. Results showed that CT-011 was safe and well tolerated with no treatment-related toxicities. Common adverse events included minimal allergic reactions and low grade fever. No single maximal tolerated dose was found in this study.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES